• Politics
  • Business
  • World
  • Science
  • Startup
  • Health
  • Travel
  • Economy
  • Top Story
Aryavarth News
  • Home
  • Politics
  • City News
  • Top Story
  • Editorial
Wednesday, February 1, 2023
No Result
View All Result
Aryavarth News
No Result
View All Result

“Corona” China Virus Vaccine Trials Stopped by Johnson & Johnson Due To Unexplained illness

Wuhan coronavirus symptoms
8.8k
VIEWS
Share on WhatsappShare on FacebookShare on TwitterShare on Telegram

New York ( Aryavarth) – Johnson & Johnson said on Monday it had temporarily paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest-profile efforts to contain the global pandemic.

The participant’s illness is being reviewed and evaluated by an independent data and safety monitoring board as well as the company’s clinical and safety physicians, the company said here in a statement.

RelatedPosts

K’taka to give Rs 1L to BPL families which lost earning member to Covid

Mass recital of ‘Hanuman Chalisa’ to end pandemic

Vax drive cheapest cost to economic normalisation: Report

J&J, which reports quarterly financial results on Tuesday morning, said that such pauses are normal in big trials, which can include tens of thousands of people. It said the “study pause” in giving doses of the vaccine candidate was different from a “regulatory hold” required by health authorities. The current case is a pause.

However, J&J’s move follows a similar one by AstraZeneca Plc. In September, AstraZeneca AZN.L paused late-stage trials of its experimental coronavirus vaccine, developed with the University of Oxford, due to an unexplained illness in a UK study participant.

While trials in the UK, Brazil, South Africa and India have resumed, the U.S. trial is still on hold pending a regulatory review.

Dr. William Schaffner, a professor of infectious diseases at the Vanderbilt University School of Medicine, said by email that “Everybody is on the alert because of what happened with AstraZeneca,” adding that it could take a week to gather information.

“It would have to be a serious adverse event. If it was something like prostate cancer, uncontrolled diabetes or a heart attack – they wouldn’t stop it for any of those reasons. This is likely to be a neurological event,” he said.

Last month, J&J said its experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, following which the company kicked off a final 60,000-person trial, whose results had been expected by the end of this year or early 2021.

Johnson & Johnson declined to elaborate on the illness due to privacy concerns. It did say that some participants in studies get placebos, and it was not always clear whether a person suffering a serious adverse event in a clinical trial received a placebo or the treatment.

Stat News reported here the pause earlier in the day citing a document sent to outside researchers, which stated that a “pausing rule” had been met, the online system used to enrol patients in the study had been closed and the data and safety monitoring board would be convened.

Tags: Covid19
SendShare811Tweet507Share

Related Posts

K’taka to give Rs 1L to BPL families which lost earning member to Covid

K’taka to give Rs 1L to BPL families which lost earning member to Covid

June 15, 2021
Mass recital of ‘Hanuman Chalisa’ to end pandemic

Mass recital of ‘Hanuman Chalisa’ to end pandemic

May 17, 2021
Vax drive cheapest cost to economic normalisation: Report

Vax drive cheapest cost to economic normalisation: Report

May 16, 2021

PM directs states to take strict action against oxygen hoarders

Aryavarth News

Copyright © 2022 Aryavarth Publication Pvt Ltd.

Navigate Site

  • About
  • Advertise
  • Privacy & Policy
  • Contact

Follow Us

No Result
View All Result
  • Politics
  • Business
  • World
  • Science
  • Startup
  • Health
  • Travel
  • Economy
  • Top Story

Copyright © 2022 Aryavarth Publication Pvt Ltd.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.